Impact of CYP2C19 polymorphisms on efficacy of clobazam therapy

Pharmacogenomics

Volumn 9, Issue 5, 2008, Pages 527-537

  Seo, Takayuki ^a   Nagata, Rie ^a   Ishitsu, Takateru ^b   Murata, Tsukasa ^a   Takaishi, Chisato ^a   Hori, Masaharu ^a   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

Clobazam; CYP2C19; Epilepsy; Genetic polymorphisms; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 2C19; DIAZEPAM; DRUG METABOLITE; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; GABAPENTIN; NORCLOBAZAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADOLESCENT; ADULT; ALLELE; ARTICLE; BEHAVIOR DISORDER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DNA INTERACTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; ENURESIS; EPILEPSY; FATIGUE; FEMALE; FOCAL EPILEPSY; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAND MAL SEIZURE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERSALIVATION; INSOMNIA; IRRITABILITY; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MONOTHERAPY; PHARMACOGENETICS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; CHILD; FEMALE; GENE FREQUENCY; HUMANS; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 44949115021     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.5.527     Document Type: Article

References (36)

1. Dicchter MA, Brodie MJ: New antiepileptic drugs. N Engl. J. Med. 334, 1583-1590 (1996).
2. Shorvon SD: Benzodiazepines: clobazam. In: Antiepileptic Drug (4th Edition). Levy RH, Mattoson RH, Meldrum BS (Eds). Raven Press Ltd, NY, USA, 763-777 (1995).
3. Ng YT, Collins SD: Clobazam. Neurotherapeutics 4, 138-144 (2007).
4. Shorvon SD: The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia 39 (Suppl. 1), S15-S23 (1998).
5. Canadian Clobazam Cooperative. Group: Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32, 407-416 (1991).
6. Kilpatrick C, Bury R, Fullinfaw R, Moulds R: Clobazam in the treatment of epilepsy. Clin. Exp. Neurol. 23, 139-144 (1987).
7. Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G: In vitro characterization of clobazam metabolism by recombinant cytochrorne P450 enzymes: importance of CYP2C 19. Drug Metab. Dispos. 32, 1279-1286 (2004).
8. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006).
9. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422 (1994).
10. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598 (1994).
11. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A: Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther. Drug Monit. 24, 737-741 (2002).
12. Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P: Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev. 26, 63-66 (2004).
13. Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T: A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 26, 530-534 (2004).
14. WHO: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992. WHO, Geneva, Switzerland.
15. Seo T, Ishitsu T, Ueda N et al.: ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7, 551-561 (2006).
16. Brodie MJ, Dichter MA: Antiepileptic drugs. N. Engl. J. Med. 334, 168-175 (1996).
17. Kwan P, Brodie MJ: Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319 (2000).
18. Ferraro TN, Dlugos DJ, Buono RJ: Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics 7, 89-103 (2006).
19. Elger C, Bialer M, Cramer JA, Maia J, Almeida I, Soares-da-Silva P: Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48, 497-504 (2007).
20. Glauser TA, Ayala R, RD Elterman et al.: Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66, 1654-1660 (2006).
21. Löscher W, Schmidt D: Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47, 1253-1284 (2006).
22. Naranjo CA, Busto U, Sellers EM et al.: A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239-245 (1981).
23. Minami K, Nemoto K, Narabe Y: A simple HPLC method for measurement of drugs. Jpn J. Clin. Chem. 33(Suppl. 3), 185 (2004).
24. Richards B, Skoletsky J, Shuber AP et al.: Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet. 2, 159-163 (1993).
25. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60, 661-666 (1996).
26. Contin M, Riva R, Albani F, Baruzzi AA: Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit. 21, 604-608 (1999).
27. Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K: Use of clobazam for the treatment of refractory complex partial seizures. Seizure 12, 282-286 (2003).
28. Montenegro MA, Cendes F, Noronha AL et al.: Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 42, 539-542 (2001).
29. Fielding S, Hoffmann I: Pharmacology of anti-anxiety drugs with special reference to clobazam. Br. J. Clin. Pharmacol. 7(Suppl. 1), S7-S15 (1979).
30. Haigh JR, Pullar T, Gent JP, Dailley C, Feely M: N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br. J. Clin. Pharmacol. 23, 213-218 (1987).
31. Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M: Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 37, 728-735 (1996).
32. Giraud C, Treluyer JM, Rey E et al.: In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab. Dispos. 34, 608-611 (2006).
33. Chiron C, Marchand MC, Tran A et al.: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356, 1638-1642 (2000).
34. Remy C: Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia 35(Suppl. 5), S88-S91 (1994).
35. Sugai K: Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia 45(Suppl. 8), 20-25 (2004).
36. Depondt C, Shorvon SD: Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. Pharmacogenomics 7, 731-745 (2006).